indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on:

crizotinib and at least one other ALK inhibitor for metastatic disease;

or alectinib as the first ALK inhibitor therapy for metastatic disease;

or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Anaplastic lymphoma kinase (ALK) inhibitor

Kinase inhibitor